GENERAL ORTHOPAEDICS
POISE 2 (Part 1): The safety and efficacy of aspirin following non-cardiac surgery
N Engl J Med. 2014 Apr 17;370(16):1494-503. doi: 10.1056/NEJMoa1401105. Epub 2014 Mar 3110,010 patients with, or at risk for, major vascular disease, and undergoing non-cardiac surgery were randomized to receive either aspirin or placebo (both with and without clonidine) as part of the Perioperative Ischemic Evaluation 2 (POISE-2) trial. This report, Part 1, summarizes the data pertaining to the safety and efficacy of aspirin, while clonidine-related data is summarized in Part 2. Results over 30 days indicated that, although the aspirin and placebo interventions yielded similar rates for the primary composite outcome (death or non-fatal myocardial infarction), significantly more patients in the aspirin group experienced major bleeding. All other efficacy and safety parameters were similar between groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
